{"id":"placebo-of-hs-25","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4297389","moleculeType":"Small molecule","molecularWeight":"421.44"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a placebo, HS-25 placebo is an inert formulation used as a control comparator in clinical trials. It is designed to match the appearance and administration route of the active HS-25 drug to maintain blinding in phase 3 studies, but contains no active drug substance and produces no pharmacological effect.","oneSentence":"This is a placebo control arm and contains no active pharmaceutical ingredient.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:08.353Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03413462","phase":"PHASE3","title":"Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2016-04-12","conditions":"Primary Hypercholesterolemia","enrollment":374},{"nctId":"NCT03433196","phase":"PHASE3","title":"Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases","status":"COMPLETED","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2016-06-07","conditions":"Hypercholesterolemia in Coronaory Heart Disease","enrollment":255},{"nctId":"NCT03464682","phase":"PHASE3","title":"Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia","status":"UNKNOWN","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2015-02-28","conditions":"Primary Hypercholesterolemia","enrollment":720},{"nctId":"NCT02087917","phase":"PHASE2","title":"A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2014-03","conditions":"Primary Hypercholesterolemia","enrollment":376}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of HS-25","genericName":"Placebo of HS-25","companyName":"Zhejiang Hisun Pharmaceutical Co. Ltd.","companyId":"zhejiang-hisun-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}